Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS

被引:54
作者
Kracke, A
von Wussow, P
Al-Masri, AN
Dalley, G
Windhagen, A
Heidenreich, F [1 ]
机构
[1] Hannover Med Sch, Dept Neurol OE 7210, D-30623 Hannover, Germany
[2] Hannover Med Sch, Dept Rheumatol, D-30623 Hannover, Germany
[3] Sophien Klin Hannover, Hannover, Germany
关键词
MS; Mx proteins; interferon beta;
D O I
10.1212/WNL.54.1.193
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To correlate Mr protein (Mx) levels in lysed blood leukocytes with the clinical response to interferon (IFN) beta-1b (IFN beta-1b) in relapsing-remitting MS (RR-MS) patients for monitoring treatment. Background: Intracellular Mx expression is exclusively induced by the type I IFNs (IFN-alpha, -beta, and -omega) or by viruses and is strongly increased under IFN treatment. Quantitative determination of Mr allows objective assessment of biological effects of IFN. Methods: Mr protein levels were measured in blood leukocyte lysates from IFN beta-1b-treated RR-MS patients by ELISA and correlated to clinical parameters, including relapse rate and clinical deterioration. Results: In stable IFN beta-1b-treated MS patients, Mr levels were significantly increased compared to patients with or without immunosuppressive treatment. In IFN beta-1b-treated MS patients during relapse, Mr levels were significantly lower than during stable phases of the disease. Mean values of Mr (MVMx) over time of treatment in patients with a reduction of relapse rate were significantly higher than in patients without response. Conclusion: Mr levels in lysed blood cells may represent a useful surrogate marker for IFN beta-1b activity corresponding to the clinical response during treatment of MS.
引用
收藏
页码:193 / 199
页数:7
相关论文
共 34 条
[1]   Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin [J].
AlMasri, AN ;
Werfel, T ;
Jakschies, D ;
vonWussow, P .
JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1997, 50 (01) :9-14
[2]   Interferon beta in multiple sclerosis [J].
Arnason, BGW .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 81 (01) :1-11
[3]   Seasonal variation of interferon-γ production in progressive multiple sclerosis [J].
Balashov, KE ;
Olek, MJ ;
Smith, DR ;
Khoury, SJ ;
Weiner, HL .
ANNALS OF NEUROLOGY, 1998, 44 (05) :824-828
[4]   INCREASED PRODUCTION OF INTERFERON GAMMA AND TUMOR NECROSIS FACTOR PRECEDES CLINICAL MANIFESTATION IN MULTIPLE-SCLEROSIS - DO CYTOKINES TRIGGER OFF EXACERBATIONS [J].
BECK, J ;
RONDOT, P ;
CATINOT, L ;
FALCOFF, E ;
KIRCHNER, H ;
WIETZERBIN, J .
ACTA NEUROLOGICA SCANDINAVICA, 1988, 78 (04) :318-323
[5]   Interferon-beta(1b) treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis [J].
Brod, SA ;
Marshall, GD ;
Henninger, EM ;
Sriram, S ;
Khan, M ;
Wolinsky, JS .
NEUROLOGY, 1996, 46 (06) :1633-1638
[6]   VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta [J].
Calabresi, PA ;
Pelfrey, CM ;
Tranquill, LR ;
Maloni, H ;
McFarland, HF .
NEUROLOGY, 1997, 49 (04) :1111-1116
[7]   PHARMACOKINETICS OF RECOMBINANT HUMAN INTERFERON-BETA(SER) IN HEALTHY-VOLUNTEERS AND ITS EFFECT ON SERUM NEOPTERIN [J].
CHIANG, J ;
GLOFF, CA ;
YOSHIZAWA, CN ;
WILLIAMS, GJ .
PHARMACEUTICAL RESEARCH, 1993, 10 (04) :567-572
[8]   Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies [J].
Deisenhammer, F ;
Reindl, M ;
Harvey, J ;
Gasse, T ;
Dilitz, E ;
Berger, T .
NEUROLOGY, 1999, 52 (06) :1239-1243
[9]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[10]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661